Drug Profile
F 17464
Alternative Names: F-17464Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antipsychotics
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-I for Schizophrenia (In volunteers) in USA (PO)
- 27 Sep 2021 Discontinued - Phase-II for Schizophrenia in France, France, Latvia, Romania, Russia, Hungary (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in USA (PO, Capsule)